BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Medtronic, Inc. (MDT) And NeuroPace, Inc. Cross License Patents For Treating Neurological Disorders; Agreement Fosters Advancements In Detection And Treatment Of Epilepsy


10/19/2005 5:09:05 PM

MINNEAPOLIS--(BUSINESS WIRE)--Aug. 4, 2005--Medtronic, Inc. (NYSE:MDT), today announced that it has entered into a patent cross-licensing agreement with NeuroPace, Inc., a privately held medical device company specializing in the detection, treatment and monitoring of epilepsy and other neurological disorders via responsive brain stimulation. Under the terms of the royalty-bearing, non-exclusive agreement, the two companies cross-licensed patents and patent applications of neurological technology related to direct electrical stimulation or monitoring of the brain. Specific terms of the agreement were not disclosed. "The agreement allows Medtronic to further develop and expand its innovative portfolio of therapies for patients suffering from neurological disorders, with the most immediate application in sensing and treating refractory epilepsy," said Jon Tremmel, president, Medtronic Neurological. "Epilepsy remains a devastating disorder for patients who don't respond to medications. A closed-loop system that can detect and prevent seizures could greatly change how physicians and patients manage this condition."

Read at BioSpace.com

   
Epilepsy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES